Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

Cancer Research

Volumn 65, Issue 20, 2005, Pages 9176-9184

  Ishikawa, Nobuhisa ^a,b   Daigo, Yataro ^a   Takano, Atsushi ^a   Taniwaki, Masaya ^a   Kato, Tatsuya ^a   Hayama, Satoshi ^a   Murakami, Haruyasu ^b   Takeshima, Yukio ^b   Inai, Kouki ^b   Nishimura, Hitoshi ^c   Tsuchiya, Eiju ^d   Kohno, Nobuoki ^b   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BIOCHEMICAL MARKER; GEFITINIB; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CANCER SURVIVAL; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; SOLID TUMOR; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 27144483349     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1556     Document Type: Article

References (23)

1. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
2. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19: 6550-65.
3. Selvaggi G, Novelle S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.
4. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749-54.
5. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gentinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46.
6. Kim YH, Ishii G, Goto K, et al. Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung. Clin Cancer Res 2004;10:7311-7.
7. Evans TL. Highlights from the Tenth World Conference on Lung Cancer. Oncologist 2004;9:232-8.
8. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gentinib. Lung Cancer 2004;45:93-104.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
10. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.
11. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-11.
12. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73.
13. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefltinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-20.
14. Kakiuchi S, Daigo Y, Ishikawa N, et al. Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib. Hum Mol Genet 2004;13:3029-43.
15. Ishikawa N, Daigo Y, Yasui W, et al. ADAMS as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004;10:8363-70.
16. Daigo Y, Chin SF, Gorringe KL, et al. Degenerate oligonucleotide primed-polymerase chain reaction-based array comparative genomic hybridization for extensive amplicon profiling of breast cancers: a new approach for the molecular analysis of paraffin-embedded cancer tissue. Am J Pathol 2001;158:1623-31.
17. Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. In collaboration with Sobin LH and pathologists from 14 countries. WHO international histological classification of tumours. Histological typing of lung and pleural tumours. 3rd ed. New York; Springer-Verlag; 1999.
18. Ebert M, Yokoyama M, Kobrin MS, et al. Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994;54:3959-62.
19. Bostwick DG, Qian J, Maihle NF. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases. Prostate 2004;58:164-8.
20. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004;22:1103-9.
21. British Thoracic Society. Guidelines on diagnostic flexible bronchoscopy. Subcommittee on Standards of Care Committee, British Thoracic Society. Thorax 2001;56:i1-21.
22. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241-9.
23. Hurbin A, Dubrez L, Coll JL, Favrot MC. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002;277:49127-33.